An SHMT/1/2 inhibitor, SHIN1, also showed efficacy in B-cell lymphoma and T-cell ALL models143, with evidence for a synergistic effect between SHIN2 and methotrexate144. This evidence concerns the gene SHMT2 and B-cell non-Hodgkin lymphoma.